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Retrocyclin-1, a -defensin, protects target cells from human
immunodeficiency virus, type 1 (HIV-1) by preventing viral
entry. To delineate its mechanism, we conducted fusion assays
between susceptible target cells and effector cells that expressed
HIV-1 Env. Retrocyclin-1 (4 M) completely blocked fusion
mediated by HIV-1 Envs that used CXCR4 or CCR5 but had little
effect on cell fusion mediated by HIV-2 and simian immunode-
ficiency virus Envs. Retrocyclin-1 inhibited HIV-1 Env-mediated
fusion without impairing the lateral mobility of CD4, and it
inhibited the fusion of CD4-deficient cells with cells bearing
CD4-independent HIV-1 Env. Thus, it could act without cross-
linking membrane proteins or inhibiting gp120-CD4 interac-
tions. Retrocyclin-1 acted late in the HIV-1 Env fusion cascade
but prior to 6-helix bundle formation. Surface plasmon reso-
nance experiments revealed that retrocyclin bound the ectodo-
main of gp41 with high affinity in a glycan-independent manner
and that it bound selectively to the gp41 C-terminal heptad
repeat. Native-PAGE, enzyme-linked immunosorbent assay, and
CD spectroscopic analyses all revealed that retrocyclin-1 pre-
vented 6-helix bundle formation. This mode of action, although
novel for an innate effector molecule, resembles the mechanism
of peptidic entry inhibitors based on portions of the gp41
sequence.
Three structurally distinct subfamilies of defensins, , , and , exist
in primates (1). -Defensins, the smallest of these and the only known
cyclic peptides of animal origin, contain only 18 residues (2). Three
-defensin peptides have been isolated from rhesusmacaque leukocytes
(3) and bone marrow (4), and intact -defensin genes exist in other
non-human primates (5). Humans have multiple -defensin genes and
express -defensin mRNA transcripts in bone marrow. However, these
genes and transcripts harbor a premature stop codon, and neither
humans nor their closest primate relatives (chimpanzees and gorillas)
produce -defensin peptides (5, 6).
Retrocyclin-1 (RC-1),3 a synthetic cyclic octadecapeptide, represents
a -defensin peptide that humans could produce if the corresponding
gene had not been silenced by mutation. Retrocyclins and other -de-
fensins exert broad spectrum antiviral properties in vitro and can pro-
tect cells from infection by HIV-1 (6–9), herpes simplex (10), and influ-
enza A viruses (11).
HIV enters a target cell after its gp120/gp41 glycoprotein (Env) binds
CD4 (12) and a co-receptor, CCR5 or CXCR4 (13). The ensuing con-
formational changes result in a 6-helix bundle (6HB) core structure
wherein three N-helical regions (N-HR) pair with three C-helical
regions (C-HR) and drive membrane fusion (14–17). Peptides that
mimic N-HR or C-HR inhibit fusion by binding their opposite counter-
part and preventing 6HB formation (18–26). Other HIV-1 entry inhib-
itors also exist and act by inhibiting CD4 binding, co-receptor engage-
ment, or affecting membrane organization (27, 28).
Retrocyclin-1 has lectin-like properties and binds glycosylated mole-
cules such as CD4, HIV gp120, and galactosylceramide with high (Kd
20–30 nM) affinity (29). Under certain conditions, this allows retrocyc-
lins to prevent viral entry by cross-linking cell surface molecules, as
recently shown for influenza A (11). Despite its activity against HIV-1,
retrocyclin-1 is considerably less effective against HIV-2 or SIV.
Because the cross-linked barrier mechanism would not explain such
selectivity, we examined the inhibitory effects of retrocyclin-1 on fusion
mediated by HIV-1 Env. We found that retrocyclin-1 prevents HIV-1
entry by binding the C-heptad repeat of gp41 in a lectin-independent
manner that prevents 6HB formation.
EXPERIMENTAL PROCEDURES
Cell-Cell Fusion Assay—Dye transfer assays, which involve observing
the transfer of fluorescent cytosolic dyes from the target cell type to a
non-labeled envelope expressing cell type, were used to quantify the
amount on envelope-induced cell-cell fusion. HIV/SIV Env-expressing
HeLa cells labeled with CMTMR and target cells labeled with calcein
were co-cultured in suspension at 37 °C. Inhibitors were added at the
onset of incubation or at various times thereafter. Phase and fluorescent
images were collected with a 10 objective lens (30, 31). Normalized
results were expressed as percent of the control fusion.
Binding Studies—Surface plasmon resonance studies were per-
formed on a Biacore 3000 instrument (Biacore, Uppsala, Sweden) in two
modes, standard and competitive (see the supplemental “Methods” sec-
tion and supplemental Table 3).
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Effect on 6-Helix Bundle Formation—Native-PAGE was done as pre-
viously described (32). Inhibition of 6HB formationwas also determined
by a modified ELISA using the mAb NC-1 (33, 34). Percent inhibition
was calculated as previously described (35). The IC50 was calculated
with Calcusyn software (36), kindly provided by Dr. T. C. Chou (Sloan-
Kettering Cancer Center, New York, NY).
CDSpectroscopy—Spectrawere obtained on a Jasco J-715 instrument
at 25 °C. Samples, diluted in 10 mMHEPES, pH 7.4, were placed in a 0.1
cm path length CD cell (Hellma, Plainview, NY). The spectra were aver-
aged from four scans, smoothed, and expressed as the mean residue
ellipticity []MRE. Additional information about cells, recombinants,
and methods is provided in supplemental “Methods and Materials,”
on-line.
Fluorescence Recovery after Photobleaching (FRAP)—FRAP was per-
formedusing aZeiss LSM510 (Carl Zeiss, Jena,Germany) confocal laser
scanning microscope. HeLa cells were plated on 35-mm glass bottom
dishes (MatTek, Ashland,MA) and transfected 24 h prior to confocal
analysis with CD4-GFP. These constructs were generous gifts from
W. Popik, and have been described previously (37). During FRAP
analysis cells were kept at physiological conditions of 37 °C and 5%
CO2 in a stage-incubation system (“Incubator S,” PeCon GmbH,
Erbach, Germany). Retrocyclin was added directly into the medium
and incubated for 10 min before commencing FRAP measurements. A
488 nm Ar laser line was used for GFP excitation and emission light
was collected with a 500–550 bandpass filter. A 40/1.3 NA oil immer-
sion objective lens was used with a zoom factor of 4. The detector
pinhole was opened slightly to acquire an optical section of 2 m thick-
ness, allowingmore light to be collected for better quantification. Three
prebleach images were acquired to determine the rate of non-purpose-
ful photobleaching. Photobleaching was performed by increasing the
transmission of the laser to 100% for 20–50 iterations to get as complete
a bleach as possible without overbleaching. After photobleaching, 8–10
images were acquired at 1-s intervals. Then the time resolution was
changed to 10 s to follow recovery to completion. A total of 20–40 data
points was acquired for image analysis.
FRAP analysis was performed using theMedical Imaging Processing,
Analysis, and Visualization (MIPAV; CIT/NIH, Bethesda, MD) soft-
ware package. Data were automatically corrected with background sub-
traction, and normalization for the non-purposeful photobleaching rate
was calculated from the whole cell. Data were analyzed using the one-
dimensional FRAP model.
RESULTS
Inhibition of Fusion—Retrocyclin-1 inhibited HIV-1 Env-mediated
membrane fusion in a concentration-dependent manner (Fig. 1a), with
an IC50 of 1.5 M, and complete inhibition at 4 M. Retrocyclin-1
inhibited fusionmediated by HIV-1IIIB (X4) and HIV-1BAL (R5) Env but
not HIV-2ROD Env (Fig. 1b). Fusion mediated by HIV-2SBL and SIVMAC
Env was slightly inhibited by retrocyclin-1. For comparison, Fig. 1 also
shows inhibition of HIV/SIV Env-mediated fusion by cyanovirin-N
(CV-N), an 11-kDa mannose-binding protein isolated from a
Cyanobacterium, Nostoc ellipsosporum, which potently inactivates
diverse strains of HIV-1, HIV-2, and SIV (38).
Excluding Potential Membrane Targets—As retrocyclin binds CD4
and glycosphingolipids (29), its inhibition of HIV-1 Env-mediated
fusion might reflect interactions with these membrane components.
We examined the fusion of CD4-independent 8x Env (39) with mouse
fibroblast 3T3 target cells bearing CD4 and CXCR4, or bearing CXCR4
alone. Retrocyclin-1 blocked 8x Env-mediated fusion with CXCR4
cells with or without CD4, indicating that its effects were independent
of gp120-CD4 interactions (Fig. 1c). The 30% residual fusion of
3T3CD4CXCR4 and 3T3CXCR4 in the presence of retrocyclin is likely
because of nonspecific background dye transfer, because cyanovirin-N,
which completely blocks HIV-1 Env-mediated fusion with various cell
types, showed the same background. Because retrocyclin-1 also inhib-
FIGURE 1. Inhibition of fusion by retrocyclin-1. a, fusion of HIV-1 Env-expressing CV-1 cells with SupT1 target cells was monitored using a dye redistribution assay. The data are
normalized to 100% fusion in the absence of inhibitor. b, retrocyclin-1 (RC-1, 4M) inhibited fusionmediated by the IIIB and BAL strains of HIV-1 Env but had considerably less effect
on Env-mediated fusion mediated by those of the SBL and ROD strains of HIV-2 and the MAC strain of SIV. For comparison, inhibition by cyanovirin-N (CV-N, 1.5 M) is shown. c,
retrocyclin-1 (4 M) substantially inhibited CD4-independent fusion of CV-1 cells expressing HIV-1IIIB 8x Env (a CD4-independent variant) with 3T3CXCR4 or 3T3CD4/CXCR4 target
cells. For comparison, inhibition by cyanovirin-N (1.5 M) is shown. Retrocyclin-1 also inhibited the fusion of HIV-1IIIB Env-expressing CV-1 cells with glycosphingolipid-deficient
GM95CD4CXCR4 targets.
TABLE 1
Effect of retrocyclin-1 on the lateral mobility of CD4
HeLa cells were transfected with CD4-GFP 1 day before measuring FRAP. The
medium contained 10% fetal bovine serum. Retrocyclin was added directly into the
medium and incubated at 37 °C for 10 minutes before FRAP measurements began.
The mobile fraction and diffusion coefficients are shown as mean S.E.
Retrocyclin Diffusion coefficient Mobile fraction n
g/ml m2/s (102)
0 2.5 0.3 94 2 26
10 4.6 0.2 98 5 21
20 3.6 0.4 97 1 22
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ited HIV-1 Env-mediated fusion with glycosphingolipid-deficient
mouse skin fibroblasts (GM95 cells) that expressed CD4 and CXCR4
(40), interactions with glycosphingolipids were not essential for its
inhibitory effects on HIV-1 (Fig. 1c).
Excluding Membrane Cross-linking—A recently described mech-
anism (11), based largely on studies with influenza A under serum-
free conditions, could account for the activity of retrocyclins against
HIV-1. In those studies, retrocyclin inhibited viral fusion by erecting
a barricade of cross-linked and immobilized surface glycoproteins.
When FRAP experiments were performed to assess the effect of
retrocyclin-1 on the lateral mobility of CD4 in medium that con-
tained 10% fetal calf serum, we found the lateral mobility of CD4 to
be intact (Table 1) and concluded that cross-linked surface barri-
cades on the target membrane did not form under the experimental
conditions used in our fusion experiments.
Temporal Analysis of the Retrocyclin Target—To dissect the kinetics
of the fusion reaction and determine at which point retrocyclin-1 loses
its inhibitory potency, we have utilized a time-of-addition experiment,
in which inhibitors are added that act at the various steps of the fusion
reaction at various times following co-culture of Env-expressing cells
with target cells. All reactions were run for 120 min, from the initial
co-culture to fusion quantification.
Time-of-addition studies were done with Leu3A, retrocyclin-1, and
C34 to assess the availability of the target of retrocyclin during the
fusion process (31). Leu3A inhibits attachment of gp120 to CD4, and
C34, a 34-residue peptide whose sequence matches the C-HR of gp41
(supplemental Fig. 1) prevents 6HB formation. Previously we had
shown that C34 operates after Leu3A (31). Fig. 2a shows that at 30 min,
by which time 50% of the HIV-1 Envs had interacted with CD4, fusion
remained 100% inhibitable by retrocyclin-1 and C34. Thereafter, retro-
cyclin-1 and C34 had identical inhibition kinetics, indicating that the
target of retrocyclin disappeared late, in a time frame similar to that of
6HB formation.
Effect of Priming—Binding HIV-1 Env to CD4 and either CXCR4 or
CCR5 triggers conformational changes that lead to viral hairpin (6HB)
formation and membrane fusion (27, 41). In the prehairpin state that
follows CD4 binding and precedes 6HB formation, N-terminal ectodo-
main regions are exposed (42), later becoming inaccessible about when
membrane fusion occurs (43). Throughout the period of accessibility,
HIV-1 Env-mediated fusion can be inhibited by peptides derived from
the N-HR or C-HR regions of gp41 (31, 41, 44).
As the time-of-addition studies (Fig. 2a) had implicated N- or C-HR
as targets for retrocyclin, we primed HIV-1 Env-expressing cells with 1
g/ml of soluble CD4 (sCD4) and either retrocyclin-1 or C34 for 1 h at
37 °C before washing and then co-culturing them with target cells.
Exposure to this suboptimal sCD4 concentration caused no inhibition,
alone or in combination with C34 or retrocyclin-1 (Fig. 2b). However,
incubating sCD4-primed cells with retrocyclin-1 or C34 inhibited
fusion, lending support to the hypothesis that retrocyclin targets the
N-HR and/or C-HR. Fig. 2b also shows that incubating either effectors
or targets with RC-1 followed by washing resulted in no fusion inhibi-
tion, indicating that the RC-1 binding to targets and unprimed effectors
is reversible.
Binding of Retrocyclin-1 to gp41—Fig. 3 compares binding of retrocy-
clin-1 to gp41HXB2, gp120LAV, and bovine serum albumin (BSA). Per
unit of mass, gp41 and gp120 bound retrocyclin-1 to an equal extent.
However, as the mass of gp120 is8 times larger than that of the gp41
ectodomain (16.4 kDa, exclusive of glycans), 8 times more retrocy-
clin-1 molecules bound a molecule of gp120 than a molecule of gp41.
supplemental Table 1 shows four experiments comparing binding of
retrocyclin-1 to gp120 and gp41. The Kd of retrocyclin-1 (mean S.E.,
n  4) for gp41HXB2 was 67.6  9.1 nM, and the Kd for gp120LAV was
33.0  4.7 nM. These differences were significant (p  0.021, paired t
test).
Because retrocyclin-1 has lectin-like properties (29) and the ectodo-
main of gp41HXB2 contains N-linked glycosylation sites, we did the
experiments shown in supplemental Table 2 to learn whether retrocy-
clin-1 bound gp41 via its N-linked glycans. By using lectins, we deter-
mined that only highmannose glycans were present in the immobilized
gp41 ectodomain. Removing these glycans with endoglycosidase H did
not decrease the binding of retrocyclin to gp41, showing that the bind-
ing of retrocyclin-1 to gp41 was not carbohydrate-related.
We next used a library of synthetic peptide fragments of HIV-1MN gp41
to determine where retrocyclin-1 might bind the gp41 ectodomain.
Two C-terminal peptides, gp41(633–650) (EREIDNYTSLIYSLLEKS)
and gp41(675–685) (DITNWLWYIK) showed the greatest binding, and
gp41(651–674) bound retrocyclin-1 to a lesser extent (supplemental Table 3).
FIGURE 2. Retrocyclin-1 inhibits HIV-1 Env-mediated fusion in a late stage of the
fusion cascade. a, time of Addition. Inhibitors Leu3a (3 g/ml), RC-1 (4 M), and C34
(2 M) were added at different times after the initial co-culture of HIV-1 Env-expressing
CV-1 cells with SupT1 target cells and the fusion was monitored using a dye redistribu-
tion assay as described under “Experimental Procedures.” b, soluble CD4-primed cells.
Fusion of HIV-1 Env-expressing CV-1 cells (E ) with SupT1 target cells (T) was monitored
using a dye redistribution assay after pretreatment of targets or effectors. The following
conditions were examined: no treatment (E0, T0); co-culture in the presence of inhibitor
(E, T); pretreatment with inhibitor of effectors, followed by washing and co-culture
with untreated targets (EW & T0); pretreatment with inhibitor of targets followed by
washing and co-culture with untreated effectors (TW/E0); incubation of effectors for
one h at 37 °C with sCD4 (40 g/ml) followed by washing and incubation with targets
(sCD4 E0 T0); incubation of effectors for one h at 37 °Cwith sCD4 inhibitor, followedby
washing and incubation with targets (sCD4 E T). The inhibitors were retrocyclin-1
(4 M) (black bars), sCD4 and C34 (2 M) (gray bars).
FIGURE 3. Binding of retrocyclin-1. Binding to gp41HXB2 ectodomain, gp120LAV, and
BSA was studied by surface plasmon resonance. Each data point is the mean of values
from two separate complete dose-response curves. The biosensor chip contained the
following amounts of attached protein: gp41, 2221 relative units (RU); gp120, 5746 RU;
BSA, 5605 RU. Each data set has been normalized to show binding to 5000 RU of immo-
bilized protein.
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Weran these surface plasmon resonance binding experiments in a com-
petitive mode, using three different biosensors: BSA, gp120LAV, and
gp41HXB2. Fig. 3 shows that binding of retrocyclin-1 to immobilized
BSA is highly linear with peptide concentration, and its binding to the
gp120 and gp41 biosensors is reasonably linear. Consequently, any of
these biosensors can be used to assess the concentration of free
(unbound) retrocyclin-1 in the presence of a potential binder, as long as
the potential binder does not itself bind significantly to the biosensor.
Indeed, with only one exception, biosensors containing BSA, gp120LAV,
or gp41HXB2 gave similar results (supplemental Table 3).
Fig. 4a shows that retrocyclin-1 bound theC34 domain ofHIV-1with
greater affinity than the C34 domains of HIV-2 or SIV. Fig. 4b shows
that BSA and gp120 biosensors detected binding between retrocyclin-1
and gp41(633–650) equally well, with an estimated IC50 of15 g/ml (7
M). Fig. 4c shows that retrocyclin bound more extensively to gp41
(HIV-1HXB2) than to gp36 (HIV-2, Biodesign R5B220). Both recombi-
nant Env glycoproteins had been expressed in yeast, Pichia pastoris. The
net anionicity of a gp41 peptide did not fully account for its ability to
bind retrocyclin-1, because gp41(651–674) (net charge, 3) bound less
well than either gp41(633–650) or gp41(675–684), with respective net
charges of 2 and 0. Nor was the net positive charge of retrocyclin-1
sufficient, because retrocyclin-1 that had been reduced and then alky-
lated with iodoacetamide no longer bound gp41, despite its undimin-
ished net charge of 4 (data not shown). Thus, topological factors
involving the placement and accessibility of the charged residues in
gp41 and retrocyclin-1 could play key roles in binding.
The gp41 ectodomains from HIV-1 strains MN, HXB2, and IIIB are
shown in supplemental Fig. 1. The HXB2 strain used in our surface
plasmon resonance experiments and the IIIB strain used in the cell
fusion experiments have identical sequences that are similar to the MN
sequence used for the gp41 peptide library. gp41(633–650), the peptide
with the greatest binding to retrocyclin-1, comprises about half of the
C34 sequence.
Retrocyclin-1 Inhibits gp41 6HB Formation—Because retrocy-
clin-1 bound the C-peptides derived from the HIV-1 gp41 C-HR
region, we considered that it might also block C-peptide/N-peptide
interactions that form the 6HB of gp41. We tested this (Fig. 5 inset)
by a native-PAGE method (32). Neither N36 (lane 1) nor retrocy-
clin-1 (lane 3) nor a mixture of the two (lane 5) show up as a band,
because their net positive charge causes them tomigrate up and away
from the gel (32). Lane 2, containing C34, shows a band near the
bottom of the gel. Lane 4, a mixture of N36 and C34 shows a less
intense C34 band and a stronger band higher in the gel that repre-
sents the 6HB, as shown by Western blots using the mAb NC-1 (32).
Lane 6 (C34  retrocyclin-1) shows a weaker C34 band, suggesting
that C34 interacted with retrocyclin-1 to form a complex with net
positive charge. When RC-1 was incubated with C34 before adding
N36 (lane 7), the intensity of the 6HB-band was significantly
reduced, compared with lane 4, showing that formation of the 6HB
was inhibited. Reduced and alkylated retrocyclin-1 (RC-1-RA),
which retains the net positive charge of retrocylin-1 but loses its
native conformation, had no significant effect on 6HB formation
(lane 8). Neither retrocyclin-1 nor RC-1-RA inhibited the 6HB for-
mation between the N- and C-peptides derived from the gp41 N-HR
and C-HR regions of SIVMac (data not shown), consistent with our
observations on its poor inhibition of SIVMac Env-mediated cell-cell
fusion.
To study the effects of retrocyclin-1 on 6HB formation more quanti-
tatively, we modified a previously described sandwich enzyme-linked
immunosorbent assaymethod usingmAbNC-1 to improve its sensitiv-
ity. As shown in Fig. 5, retrocyclin-1 inhibited gp41 6HB formation in a
dose-dependent manner, with an IC50 value of 0.585  0.012 M. In
contrast, reduced and alkylated RC-1 showed no inhibition at up to 100
FIGURE 4.Bindingof retrocyclin-1 toC34peptides. a, retrocyclin-1 (1g/ml)wasmixedwith various concentrations of C34 peptides fromHIV-1, HIV-2, and SIV. This biosensor chip
contained 5545 RU of immobilized BSA, and showed negligible binding of C34. b, biosensor chips onwhich either BSA or gp120 had been immobilized gave very similar results, here
illustrated by gp41(633–650) from HIV-1. In a and b, binding (percent of control) is expressed relative to binding by retrocyclin-1 in the absence of C34 peptide. The concentrations of
the C34peptideswere establishedbyquantitative amino acid analyses. c, binding of retrocyclin-1 to recombinant gp41 fromHIV-1 greatly exceeded its binding to immobilized gp36
from HIV-2. Both recombinant glycoproteins were expressed in a yeast, P. pastoris, and were immobilized to a similar density (2000 RU) on the biosensor chips.
FIGURE5.Retrocyclin-1 inhibits gp416HB formation. Enzyme-linked immunosorbent
assay results shown. Serial 2-fold dilutions of RC-1 (closed circles) or its reduced and
alkylated derivative (RC-1a) (open circles), from 100 to 0.5 M, were tested in duplicate.
Data are presented in Mean  S.D. A repeat experiment in duplicate gave the same
result. Inset, N-PAGE.N36 (N) and/orC34 (C) heptad repeatpeptides fromHIV-1HXB2gp41
werepreincubatedwith retrocyclin-1 (R), with reducedandalkylated retrocyclin-1 (R*) or
phosphate-buffered saline at 37 °C for 30 min before loading the mixtures onto the gel.
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M.The ability of retrocyclin-1 to inhibit 6HB formationwas also exam-
ined by CD spectroscopy (Fig. 6). In the absence of retrocyclin-1, an
equimolar mixture of N36 and C34 (12.5 M) gave a characteristic
-helical spectrum (Fig. 6a), and retrocyclin-1 showed a -sheet spec-
trum as reported elsewhere (8). The addition of 5 M retrocyclin-1 to
the N36/C34 mixture reduced its mean residue ellipticity at 222 nm by
about half, and larger concentrations of retrocyclin-1 further attenuated
the signal (Fig. 6b).
Structural Features—Fig. 7 shows structural representations of C34
and of retrocyclin-1. The arginine residues of retrocyclin-1 appear well
positioned to allow at least three of them to interact with accessible
anionic carboxyl groups on the exterior helical surface of C34.Whether
these hypothesized anionic docking sites suffice to allow retrocyclin-1
to sabotage 6HB formation and the fusion machinery of HIV-1 or
whether additional binding interactions also participate awaits further
investigation.
DISCUSSION
We used retrocyclin-1, a model peptide, to learn how -defensins
frustrate the molecular machinery used by HIV-1 to enter target cells.
We previously reported that the ability of retrocyclin-1 analogues to
protect cells from HIV-1 was highly correlated to their ability to bind
gp120 and CD4. We have also shown that much of their binding to
gp120 and CD4 results from their lectin-like carbohydrate binding
properties (29). Yet the present experiments demonstrate that retrocy-
clin-1 can block HIV-1 entry independently of interactions with gp120
and/or CD4 and independently of glycoprotein binding.
How might this paradox be explained? Other studies, to be pre-
sented elsewhere, indicate that the arginine residues of retrocyclin-1
play an essential role in carbohydrate binding. If the same arginines
endow -defensins with their ability to bind the C-terminal heptad
repeat of gp41, as depicted in Fig. 7, then the correlation between
carbohydrate binding and activity against HIV-1 is readily under-
stood. The ability of gp41(675–685) (DITNWLWYIK) to bind retrocy-
clin-1 effectively (supplemental Table 3) suggests that the electro-
static interactions suggested by Fig. 7 may be reinforced by
additional binding interactions, perhaps involving the isoleucine and
cysteine residues of retrocyclin.
The mechanism whereby retrocyclin-1 inhibits HIV-1 entry closely
resembles the mechanism of gp41-based peptide inhibitors of HIV-1
mediated fusion (18–26;45). Each of these well characterized HIV-1
inhibitory peptides contains one or more gp41 domains that would
normally interact to form 6HBs and drive membrane fusion (41). By
binding exposed prefusion sites on gp41, these peptides prevent the
formation of the 6-helix, coiled-coil structure and block fusion and
downstream entry events (26, 27, 31, 41, 44).
Retrocyclin-1 selectively targeted the C-terminal heptad repeat
region of the HIV-1 gp41 ectodomain, and it inhibited 6HB formation
between peptides derived from the N- and C-terminal heptad repeat
regions of HIV-1 gp41. The finding that retrocyclin-1 had substantially
less effect on 6HB formation between the SIV N- and C-peptides is
consistent with its lesser effectiveness against this virus. The mecha-
nism described in this report also offers a testable hypothesis to explain
why some primary HIV-1 isolates (e.g. those of clade C (9)) are more
resistant to retrocyclin-1 than the more uniformly sensitive clade B
isolates represented by the gp41 peptides used in this study.
FIGURE 7. C34 and retrocyclin-1: structures and potential interactions. The back-
bone of C34 (PDB ID code 1AIK) is shown in ribbon format, highlighting its helical struc-
ture. The backbone (green) of retrocyclin-1 is in stick format, with its disulfide bonds in
yellow. The side chains of glutamic acid (red) and arginine (blue) residues are in ball-and-
stick format for C34 and the arginine side chains of retrocyclin-1 are in stick format. The
Arg side chains of retrocyclin-1 (blue) are oriented to highlight possible interactionswith
the negatively charged residues of C34. Two retrocyclin-1 molecules and one C34 are
shown.
FIGURE 6. CD spectroscopy evidence that retrocyclin-1 blocks 6HB formation. a, the CD spectrum of an equimolar mixture, 12.5M each, of HIV-1MN N36 and C34, shown by the
solid line, has features typical of -helical structure. The dashed line shows the spectrum of 50M retrocyclin-1 (abbreviated as RC100, which is the same as RC-1), and the dotted line
shows the spectrum of a mixture of 12.5 M N36, 12.5 nM C34, and 50 M retrocyclin-1. b, CD spectroscopy was performed onmixtures containing 12.5 M HIV-1 N36, 12.5 M HIV-1
C34, and 0–50 M retrocyclin-1. The addition of retrocyclin-1 caused a concentration-dependent disappearance of the -helical spectrum of the N36C34 mixture.
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The mechanism of inhibition of HIV-1 entry by retrocyclin-1
revealed in this study is very similar to that exhibited by N- and C-pep-
tides derived from the HIV-1 gp41 N-HR and C-HR, including the only
fusion inhibitor approved by the FDA for antiretroviral treatment (T-20
or enfuvirtide). Further confirmation of this mechanism has been pro-
vided by recent studies of in vitro selection of HIV-1 resistance to ret-
rocyclin-1 (46). This study reports that passaging HIV-1 under selective
pressure by RC-101, a retrocyclin analog, results in a 5–10-fold decrease
in viral susceptibility to RC-101. Emergent viral isolates had three amino
acid substitutions in their envelope glycoprotein. One was in a CD4-
binding region of gp120, and the others were in the HIV-1 gp41 N-HR
and C-HR. Eachmutation replaced an electroneutral or electronegative
residue with one that was positively charged, consistent with the model
shown in Fig. 7, which shows anionic docking sites for RC-1 in WT
HIV-1gp41.
The present experiments did not directly test the “cross-linked bar-
rier” mechanism delineated by recent studies with influenza A (11).
Those studies, unlike the present ones, were conducted under serum-
free conditions. Influenza A infections are initiated on the air side of a
respiratory tract interface, potentially a serum-free environment.
Serum-free conditions could also be relevant to sexually transmitted
HIV-1 infection, where the virus begins its odyssey by interacting with
mucosal cells in an environment containing little or no serum. In serum-
poor environments, the barrier mechanism (11) and the mechanism
defined in this report could co-exist and reinforce each other.
Carbohydrate binding properties may enhance the antiviral proper-
ties of -defensins in additional ways. Their ability to bind carbohydrate
residues on gp120 and CD4, and to bind numerous target cell mem-
brane constituents (e.g. glycoproteins, glycolipids, and glycosaminogly-
cans), will establish high local concentrations of -defensins exactly
where (andwhen) its vulnerable prehairpin structure becomes exposed.
At present, -defensin peptides are reflections of the past of the human
innate immune system. However, based on their small size and intrigu-
ing properties, should it become possible to design similar viral inhibi-
tors, -defensins may play a significant role in protecting humans
against future infectious challenges.
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